Cost-effectiveness of screening for HLA-A∗31:01 prior to initiation of carbamazepine in epilepsy

Epilepsia

Volumn 56, Issue 4, 2015, Pages 556-563

  Plumpton, Catrin O ^a   Yip, Vincent L M ^b   Alfirevic, Ana ^b   Marson, Anthony G ^b   Pirmohamed, Munir ^b   Hughes, Dyfrig A ^a  

^a BANGOR UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

31:01; Carbamazepine; Cost effectiveness analysis; Cutaneous adverse drug reaction; HLA A; Pharmacogenetics

Indexed keywords

CARBAMAZEPINE; HLA A ANTIGEN; LAMOTRIGINE; ANTICONVULSIVE AGENT; HLA-A*31:01 ANTIGEN;

ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRESS SYNDROME; DRUG EFFICACY; EPILEPSY; GENOTYPE; HUMAN; MACULOPAPULAR RASH; NATIONAL HEALTH SERVICE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REMISSION; SENSITIVITY ANALYSIS; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ADULT; COST BENEFIT ANALYSIS; DECISION TREE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECONOMICS; GENETIC SCREENING; GENETICS; MALE; PROCEDURES;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPILEPSY; GENETIC TESTING; HLA-A ANTIGENS; HUMANS; MALE;

EID: 84927579325     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12937     Document Type: Article

References (32)

1. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-1138.
2. Pirmohamed M, Friedmann PS, Molokhia M, et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 2011; 89: 896-901.
3. McCormack M, Alfirevic A, Bourgeois B, et al. HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143.
4. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson Syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 133: 1197-1204.
5. Yip VL, Marson AG, Jorgensen AL, et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012; 92: 757-765.
6. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013; 94: 324-328.
7. Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B∗15:02 and HLA-A∗31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; 55: 496-506.
8. Genin E, Chen DP, Hung SI, et al. HLA-A∗31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J 2014; 14: 281-288.
9. Dong D, Sung C, Finkelstein EA,. Cost-effectiveness of HLA-B∗1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259-1267.
10. Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, et al. Economic evaluation of HLA-B∗15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia 2013; 54: 1628-1638.
11. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet 2007; 369: 1000-1015.
12. Valproate summary of product characteristics. Available at: http://www.medicines.org.uk/. Accessed February 24, 2014.
13. National Institute of Health and Care Excellence. The Epilepsies: clinical practice guideline. 2012. Available at: http://www.nice.org.uk/guidance/cg137. Accessed February 6, 2015.
14. Tudur Smith C, Marson AG, Chadwick DW, et al. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007; 8: 34.
15. Saramago P, Manca A, Sutton AJ,. Deriving input parameters for cost-effectiveness modeling: taxonomy of data types and approaches to their statistical synthesis. Value Health 2012; 15: 639-649.
16. The allele frequency net database. Available at: http://www.allelefrequencies.net. Accessed May 15, 2013.
17. Lamotrigine summary of product characteristics. Available at: http://www.medicines.org.uk/. Accessed December 11, 2013.
18. Carbamazepine summary of product characteristics. Available at: http://www.medicines.org.uk/. Accessed December 11, 2013.
19. Human mortality database. Available at: www.mortality.org. Accessed June 6, 2012.
20. Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006; 5: 481-487.
21. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026.
22. Poole CD, Chambers C, Allsopp R, et al. Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids. J Eur Acad Dermatol Venereol 2010; 24: 674-678.
23. Hofhuis JG, Spronk PE, van Stel HF, et al. The impact of severe sepsis on health-related quality of life: a long-term follow-up study. Anesth Analg 2008; 107: 1957-1964.
24. Haber J, Hopman W, Gomez M, et al. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005; 26: 33-41.
25. Öster C, Willebrand M, Dyster-Aas J, et al. Validation of the EQ-5D questionnaire in burn injured adults. Burns 2009; 35: 723-732.
26. Ara R, Brazier J,. Predicting the short form-6D preference-based index using the eight mean short form-36 health-related utilities when patient level data are not available. Value Health 2009; 12: 346-353.
27. Curtis L,. Unit costs of health and social care 2011. Canterbury: Personal Social Services Research Unit, University of Kent; 2011.
28. Fenwick E, Claxton K, Sculpher M,. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779-787.
29. Husereau D, Drummond M, Petrou S,; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013; 16: 231-250.
30. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available at: http://publications.nice.org.uk/pmg9. Accessed February 6, 2015.
31. Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013; 84: 1138-1147.
32. McCormack M, Urban TJ, Shianna KV, et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics 2012; 13: 399-405.